TNFRSF13C抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: Mouse thymus tissue, Primary antibody: P05098(TNFRSF13C Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P05098(TNFRSF13C Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P05098(TNFRSF13C Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

TNFRSF13C, also known as the BAFF receptor (BAFF-R) or CD268. is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a critical role in B-cell survival, maturation, and immune regulation. It binds to B-cell activating factor (BAFF, TNFSF13B), a cytokine essential for maintaining peripheral B-cell homeostasis. TNFRSF13C is primarily expressed on mature B cells and mediates signaling through the NF-κB and MAPK pathways, promoting cell survival and proliferation. Dysregulation of this pathway is implicated in autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis) and B-cell malignancies.

Antibodies targeting TNFRSF13C are vital tools for studying its function and therapeutic potential. These antibodies can block BAFF/BAFF-R interactions, modulate downstream signaling, or detect receptor expression in experimental assays like flow cytometry, immunohistochemistry, or Western blot. In research, they help elucidate mechanisms of B-cell hyperactivity in autoimmune conditions or resistance in lymphoproliferative disorders. Clinically, anti-TNFRSF13C strategies (e.g., monoclonal antibodies, fusion proteins) are explored to suppress pathogenic B-cell activity, though most remain in preclinical or early-phase trials. Challenges include balancing efficacy with potential immunosuppression risks. Overall, TNFRSF13C antibodies provide insights into immune dysregulation and pave the way for targeted therapies in B-cell-mediated diseases.